It’s important to remember, though, that these areas of study are still very new and in their early stages. This makes it hard to predict just how far their reach and impact will be. Combined with lifestyle and dietary changes, prescribed cannabinoid use will very likely be a pivotal intervention in the future of obesity and diabetes management and recovery.
CBD is not often marketed as a weight loss aid, but studies show that it does have the potential for helping people to shed excess pounds. Cannabidiol has been heavily researched by independent organizations, and anecdotal evidence on its benefits for weight loss are widely available. Yet, until recently, the federal government persisted in classifying it as a controlled substance, even though it is nonaddictive, non-psychoactive, is not mood altering, and is safer than aspirin.
This study combats the notion that CBD causes a THC high by discussing the misinterpretations of prior studies on the subject. In fact, the researchers state that two particular prior studies “have caused much confusion and uncertainty whether oral cannabidiol (CBD) is safe and whether subjects who are treated with CBD run the risk of positive workplace tests [for THC].”
This study investigated how CBD could affect subjects with liver injuries resulting from chronic and binge alcohol consumption. CBD was given to subjects (in this case, mice and human blood samples) that had been fed alcohol. In short, the analysis demonstrated that CBD lessened the elevated liver enzymes and the increased liver triglyceride. It also reduced fat droplet accumulation.
While overstimulation of the CB1 receptor may lead to symptoms such as high blood pressure and abnormally high cholesterol levels, CBD is a CB1 antagonist, so it is not likely to cause such issues. Furthermore, the World Health Organization has recently issued a global report on CBD, claiming that it has a good safety profile and minimal adverse public health effects.